Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies

Leukemia Research
Karim MalekD G Wright

Abstract

Six patients with bcr-abl positive AML or chronic myelogenous leukemia in blast crisis (CML-BC) were treated with the IMP-dehydrogenase (IMPDH) inhibitor, Tiazofurin, in a Phase-II trial. Tiazofurin was given by IV infusion (2200-2700 mg/m2 per day) for up to 10 days. Leukemia blasts rapidly disappeared from the circulation of patients during treatment, while mature myeloid cells in the marrow increased in number. Although these hematologic responses were transient, persisting less than 3-4 weeks, our findings confirm that Tiazofurin has anti-leukemia activity. This drug warrants further study in combination regimens with other chemotherapeutic agents for the treatment of bcr-abl positive AML and CML-BC.

References

Nov 1, 1991·Molecular and Cellular Biology·D A GlesneE Huberman
Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·E OlahJ Sugar
Jun 15, 1986·Biochemical Pharmacology·H N JayaramG Weber
Sep 30, 1983·Biochemical and Biophysical Research Communications·D L LucasD G Wright
Dec 1, 1983·The Journal of Clinical Investigation·D L LucasD G Wright
Jan 25, 2002·Blood·Martin S TallmanJacob M Rowe
Mar 1, 2002·The New England Journal of Medicine·Hagop KantarjianUNKNOWN International STI571 CML Study Group
Jul 25, 2003·Cancer·Guillermo Garcia-ManeroHagop M Kantarjian

❮ Previous
Next ❯

Citations

Aug 30, 2012·Journal of Biomolecular Structure & Dynamics·Hridoy R Bairagya, Bishnu P Mukhopadhyay
Dec 1, 2012·Molecular Pharmacology·Yi-Ching HsiehEmine Ercikan Abali
Jul 16, 2010·Leukemia & Lymphoma·Katherine L B Borden, Biljana Culjkovic-Kraljacic
Aug 19, 2008·Biochemical and Biophysical Research Communications·Keith TanKatherine L B Borden
Mar 30, 2017·Pharmacology & Therapeutics·Daniel NguyenHua Lu
Sep 14, 2019·Cancers·Rand NaffoujeAtsuo T Sasaki
Dec 13, 2007·The Oncologist·Mary E King, Jacob M Rowe
Apr 21, 2020·Biochemical Society Transactions·Davide M FerrarisMenico Rizzi
Apr 21, 2021·Cell Cycle·Danilo CucchiSarah A Martin
Jul 22, 2006·Advances in Enzyme Regulation·Edith OláhMárton Keszei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.